AACI (Association of American Cancer Institutes)’s Post

We're peresent at the ACS Conference! Representing us at the event is Kishore V Renduchintala, Our Executive Vice President & Head of Discovery Services and Vidya Sagar K. - Head of Business Development - Discovery Services. Meet us at the ACS Conference to learn more about Laxai and explore a partnership that could revolutionise the approach to drug discovery and development. To book a meeting, reach out to [email protected]. We look forward to connecting with you at the event! hashtag #ACSConference #LAXAI #DrugDiscovery #CRDMO #SmallMolecules

Meet Ji Yeon Lee, our Associate Scientist II, Antibody and Protein Sciences. Ji has played a pivotal role in helping to build and optimize Mythic’s foundational antibody production capabilities. We thank Ji for her passion, dedication and for being such an integral part of our Mythic team. As we strive to realize the transformative impact of #ADCs for more patients, Ji reflects on a memorable moment at Mythic, below:  #MeetMythic #MythicProud 

FogPharma CEO Mathai Mammen, M.D., Ph.D., will be at the rEVOLUTION Symposium this week in Washington, DC, to moderate a panel on the inevitability and utility of AI in the development of therapies for patients. The rEVOLUTION meeting is held every 1-2 years in DC, and brings together thought leaders to tackle some of R&D’s most significant challenges. The location also allows significant participation by DC’s policymakers and regulators.   Joining Mathai for this important discussion will be Nicolle Gatto, Ph.D., Chief Scientific Officer at Aetion; Najat Khan, PhD, Former Chief Data Science Officer & Global Head, Strategy & Portfolio, R&D at Johnson & Johnson; Eric Schadt, Ph.D., Chief Scientific Officer at Pathos; and other leaders.    AI, and data science broadly, are technologies we’re passionate about at FogPharma. Today, a lot of attention is being paid to the role of data science in drug discovery, but in fact some of the biggest gains in the near term will be made in drug development. Numerous resource-intensive, strategically critical drug development challenges — including clinical site selection, patient recruitment, protocol design, endpoint definition, responder and non-responder signatures, and synthetic control arms — will be revolutionized by data science in the coming years.   At Fog, we hope to combine experimental science and these sorts of data science advances to revolutionize the discovery and development of transformational medicines.    Explore the rEVOLUTION event agenda here:  https://bit.ly/44jUIoH   #drugdiscovery #artificialIntelligence #datascience #oncology

🎯 Analyzing Performance of the Twist Bioscience Exome Kit Leveraging VS-CNV This Golden Helix, Inc. webcast on Wednesday, February 21st, will cover: • The sensitivity rate for the detection of known CNV events at all three probe densities. • The impact of best-practice quality metrics and filters on sensitivity. • How VarSeq’s CNV annotation capabilities can be leveraged to identify likely pathogenic CNVs. • The interpretation of clinically relevant CNVs using VSClinical. Register here: https://lnkd.in/evQXwG8F #clinical #wholeexomesequencing #CNV #VarSeq #VSClinical #GoldenHelix

Planning out your schedule for #SCOPE2024 next week? Our VP of Scientific Operations & Development, Mark Melton, MSc, is participating in a panel you won't want to miss if you've been struggling with Biomarker and PK samples in your trials. Joined by several industry experts, he'll explore how industry standardization can accelerate #precisionmedicine operations. #clinicaltrials #clinicalresearch #biomarkers #PKsamples #SCOPE #samplereconciliation #clinicaloperations

Will you be in Boston for #NextGenOmicsUS24 this week? Don't forget to stop by booth 14 to meet Paul Reid and learn how Genseq's multiomic services can help you maximise the potential of your samples to elevate your research, discovery, and clinical trial efforts. Please feel free to message us or Paul Reid before the event to arrange a chat! #OGOmics #NextGenOmicsUS24 #multiomics

Hello #ESHG2024 attendees! Come to booth #428 for one of our 5-min product demos where we showcase our latest software innovations. If you attend one of these demos, you will receive one of our famous t-shirts. 10:10 - Somatic NGS Workflow with VarSeq - Streamlining Tertiary Analysis with Oncogenicity Classifier and CancerKB 12:10 - PGx: Pharmacogenomics Workflow 12:40 - VarSeq Dx: Using the VarSeq Suite as a Medical Device Under IVDR 13:10 - Whole Genome Analysis with Long Read Data 13:40 - Carrier Status Analysis in VarSeq 15:40 - NGS Enterprise Capabilities - Automation, Warehousing, Continuous Improvement 16:40 - Calling CNV with Twist Exome 2.0 #ESHG #Genetics #NGS #PrecisionMedicine

Digital therapeutics (DTx) is still in its early stages in the Lifesciences industry, whereas many other sectors, including heavily regulated ones like banking, financial services, and insurance (BFSI), transitioned to digital solutions a decade or more ago. As Pharma embraces digital therapeutics, it's crucial to focus not only on marketing and sales strategy but also on robust data analytics to support the successful launch and ongoing success of DTx products. By incorporating insights from industries that have already navigated the digital transition, Pharma can create more effective, secure, and patient-centric digital therapeutic solutions. Be sure to join the session to learn more about how we're helping a client launch a novel digital therapeutic, exploring these strategies and best practices to ensure a successful outcome.

Hats off to Insilico Medicine, Alex Zhavoronkov, Feng Ren, 4B Technologies, Ltd for completing phase 2 patient enrollment for the fully AI-developed ALS drug. By target identification with PandaOmics, and further drug development, this partnership gave hope to tackling the currently untreatable disease in less than 2 years since the project started. This highlights the power of #AI drug development, and it's crucial role in minimizing the burden of disease. Kudos!

If you’re attending ISCTM in Washington, DC, this week, don’t miss Dr. Joseph Geraci and Dr. Larry Alphs from NetraMark, where they’ll be presenting a poster THURSDAY EVENING on evaluating drug efficacy in clinical trials by leveraging AI-generated insights from placebo response modeling using NetraAI.    The NetraAI platform allows scientists to examine small, multimodal datasets in CNS trials to uncover connections related to efficacy, toxicity and placebo response. This accelerates traditional drug development through improved understanding of the underlying disease and mechanism of action, improving clinical trial designs and reducing expensive failures.   #NetraAI #ClinicalResearch #CNS #ISCTM